Associated Papers
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
Pfeil AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
Pfeil AJ et al.
Biorxiv : the Preprint Server for Biology, 2025
Genomic landscape of endometrial polyps.
Reinikka S et al.
Genome Medicine, 2025
41137179 (PubMed )
Supplement: 13073_2025_1556_MOESM1_ESM.xlsx › S3
Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors.
Clavaín L et al.
Oncogene, 2023
Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma.
Ilcus C et al.
Journal of Personalized Medicine, 2021
CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways.
Schulte SL et al.
Oncotarget, 2016
Select a paper to view details